ArticleObesity surgery2025
Multicenter Retrospective Analysis of Consecutive Swallowable Gastric Balloon Treatments in a Community Obesity Care Setting.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have demonstrated safety and effectiveness of the swallowable gastric balloon program (SGBP) for weight loss. If additional weight loss is desired, consecutive balloon treatments may be an adjunct treatment. The goal was to evaluate the safety and effectiveness of consecutive placements of the SGB in adults with overweight and obesity.
methodsData on weight loss (WL), total body weight loss (%TBWL) and adverse events were retrospectively collected on patients who received consecutive SGBs between March 2017 and November 2023. The first SGB was swallowed and filled with 550 mL of distilled water in an outpatient setting. A second SGB was placed following passage of the first for additional weight loss. Lifestyle and nutritional follow-up were performed.
resultsIn total 121 patients underwent consecutive SGB treatment. Baseline mean age, weight, and BMI were 43.6 ± 11.1 years, 102.6 ± 22 kg, and 36.4 ± 7.0 kg/m
conclusionsConsecutive SGBs treatment was safe and effective when additional weight loss was desired following passage of the first balloon.
Indexed as
Identifiers
41037243What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.